menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Trump Joins the War on Cancer... on the Side of Cancer

13 0
23.04.2026

Last week marked one year of me being cancer free. I’ve shared parts of the story of my excruciating recovery on a couple occasions. Still, it’s been truly surreal to embark on this journey back to health while being inundated with report after report of Trump administration policies that seem intent on increasing the suffering caused by cancer. Where normal governments seek to protect people through research, medical innovation, and funding for early treatment and prevention, this administration has slashed research into cancer, cut funding for medical care, and moved to relax standards on how much exposure to carcinogens companies are allowed to inflict on surrounding communities. This is, in short, a pro-cancer government.

Every administration has been guilty of taking actions that jeopardized public health, but there is simply nothing that can compare to the scale and breadth of Trump 2.0’s across-the-board evisceration of every part of the government that helps with cancer prevention and treatment. For half a century, the United States waged a War on Cancer. Since January 2025, it has instead waged war on cancer’s victims.

Cutting Cancer Research

The most obvious part of the Trump administration’s war on cancer patients is the frontal assault on research seeking to develop new screenings, treatments, and, hopefully, cures for an array of cancers.

On January 21, 2025, his first full day back in office, President Donald Trump imposed a bevy of restrictions on the National Institutes of Health (NIH), including functionally freezing external communications, grant review, and employee travel. By executive fiat, Trump and his right hand man-domestic policy puppet master Russell Vought delayed the disbursement of the NIH’s $47 billion in research funds, including $7 billion under the aegis of the National Cancer Institute (NCI). This consequently forced a pause on the review and approval of new clinical oncology trials. At the end of his second week in office, Trump mandated an instant 15% cap on NIH grant overhead, effectively demanding that the agency spend $4 billion less than planned. After freezing funding until the start of February, the NIH then began ruthlessly, frequently illegally (according to multiple federal court decisions) terminating grants; more than 1,800 were ended between February and June. And while courts have restored many of the improperly terminated grants, there’s a lot less recourse for new grants that are not being issued, leaving many research labs across the country, “running on fumes,” as The Washington Post described it. According to the Post’s analysis, NIH grants this year have fallen by over 50%.

The current suits in the White House would like you to believe the idea of a moonshot to treat cancer and the usage of words like “woman” in scientific research is more controversial than the erosion of decades of medical research and mass defunding of investment in curing one of the most omnipresent diseases in human history.

From the start of this term, the administration has also censored the production and dissemination of federal health research from agencies like the Centers for Disease Control and Prevention (CDC) and the NIH. This includes illegally scrubbing swathes of publicly available data and web resources and requiring approval from the administration for CDC scientists to publish in external journals. The CDC mandated that no research publication was to use a list of supposedly “DEI” terms, including “LGBTQ” and “biologically female.” In other instances, any inclusion of the word “race,” “gender,” “sex,” “pregnancy,” or even “woman” was grounds for censorship. The result has been a chilling of important investigations that impact how we treat cancer; the type of tumor I had (called a carcinoid) occurs most often in older women.

The CDC, though, would not let a researcher publish that last sentence, if it had its way.

On April 1 2025, four NIH institute directors and another acting director were placed on leave. By late April, the chaos of a rampaging DOGE and mass layoffs had already forced out at least 2,500 staff (more than 10% of the agency’s 20,000 headcount) including two dozen of the 320 in-house research physicians at the NIH Clinical Center. After some of the internal administration restrictions were eased, researchers were still dealing with massive backlogs for basic lab equipment. That May, the administration sent a stop work order to the SMART IRB system, an NIH-funded initiative that streamlined institutional review board approval for clinical trials used by more than 1,300 institutions. A career researcher at NIH told Science that “however bad everyone on the outside thinks it is, it is a million times worse.”

All in all, the NIH has seen a proposed 44% funding cut, with the NCI facing a 37% cut. And it isn’t just NIH; there have been major reductions in cancer research funding from the Department of Defense and the Department of Veterans Affairs as well. A $1.5 billion Pentagon-directed health research grant fund, about half of which was devoted for cancer research, was slashed by 57%; funding for kidney, pancreatic, and lung cancer were zeroed out. At the VA, DOGE deployed an inaccurate data tool that terminated numerous grants, including one gene sequencing device that was being used to research cancer........

© Common Dreams